Clinical trial
Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of…
NCT00473668 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00473668 |
|---|---|
| Title | Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib |
| Official title | Non-inferiority of One Formulation of GSK Biologicals' DTPw-HBV/Hib to 2 Formulations of GSK Biologicals' DTPw-HBV/Hib With Respect to the Immune Response to the PRP Antigen, When Administered to Healthy Infants at 6, 10, 14 Weeks of Age |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Whole Cell Pertussis, Haemophilus Influenzae Type b, Tetanus, Diphtheria, Hepatitis B |
| Intervention type | Biological |
| Interventions | Zilbrix-Hib, Tritanrix™-HepB/ Hiberix™ |
| Enrollment | 300 |
| Start date | Jun 1, 2007 |
| Primary completion | Jan 30, 2008 |
| Completion | Jan 30, 2008 |
| First posted | May 15, 2007 |
| Last update posted | Aug 18, 2017 |
| Countries | India |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: